Just caught something interesting - looks like Braidwell trimmed their Xenon stake pretty hard in Q4, dumping nearly 1.8 million shares for about $75 million. That's a solid chunk of their portfolio gone right before what could be a make-or-break moment for the company.

Xenon's Phase 3 data on azetukalner for focal seizures was supposed to drop in March, so the timing of this move is kind of telling. They went from a bigger position down to like 2.6% of their fund AUM - still meaningful, but definitely not a core holding anymore. Feels like a deliberate de-risking move rather than a panic sell.

Here's what caught my eye though: they didn't completely bail. Kept over 1.8 million shares worth roughly $82 million at quarter-end. So it's not like they lost faith in Xenon entirely - more like they're hedging before the clinical data hits. Makes sense for a biotech portfolio. You spread your bets across multiple late-stage programs instead of going all-in on one binary event.

Xenon's up only about 6% over the past year, which is pretty weak for biotech. The stock's been volatile. Now we're past that March deadline they were waiting for, so the real question is whether those Phase 3 results came through. That's the actual catalyst that moves the needle here, not institutional shuffling. But moves like this one always make you wonder what smart money is thinking ahead of the data drop.